A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

Effect of LY3314814 on the Pharmacokinetics of Dabigatran in Healthy Subjects

The purpose of this study is to learn about the effect of lanabecestat on how the body absorbs and processes dabigatran etexilate and how dabigatran etexilate affects lanabecestat when they are taken together. This study will last about 28 days and participants will be asked to take an lanabecestat tablet daily for 19 days and a dabigatran etexilate tablet on 3 occasions. Screening is required within 30 days prior to the start of the study.

Inclusion Criteria:

- Overtly healthy males and females

Exclusion Criteria:

• Eye abnormalities or disease
• History of vitiligo or any skin color disorder
• Have a history psychiatric or brain disease including seizures
• Have smoked within the last 3 months
• Are unwilling to avoid food and drinks containing grapefruit or Seville oranges for the duration of the study
• Have known allergies to dabigatran etexilate and related compounds